View in EDS

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.

Saved in:
Bibliographic Details
Title: Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.
Authors: Costa, L. J.1 ljcosta@uabmc.edu, Bahlis, N. J.2, Perrot, A.3, Nooka, A. K.4, Lu, J.5, Pawlyn, C.6,7, Mina, R.8, Caeiro, G.9, Kentos, A.10, Hungria, V.11, Reece, D.12, Niu, T.13, Mylin, A. K.14, Hansen, C. T.15, Teipel, R.16, Besemer, B.17, Dimopoulos, M. A.18,19, Zamagni, E.20,21, Yoshihara, S.22, Kim, K.23
Source: New England Journal of Medicine. 2/19/2026, Vol. 394 Issue 8, p739-752. 14p.
Database: Academic Search Ultimate
Be the first to leave a comment!
You must be logged in first